把癌症攔截在早期

與我們的投資者攜手共創未來

Mirxes Holding Co. Ltd.

2629.HK

作為東南亞首家在香港交易所上市的生物科技公司,我們致力於利用專有科技、綜合「端到端」能力以及緊密的合作夥伴關係,加速在主要亞太市場及其他地區的成長。我們邀請您瀏覽此頁面,查閱財務報告、公司公告和演示文稿。這些資料都突顯了我們通過早篩挽救生命和驅動長期股東價值的使命。

公告與通函

其他重要資訊

公司治理
財務報告
投资者演示文稿
分析師報告

Featured

A Future Without Late Diagnosis

Harnessing RNA science to detect cancer early and save lives.

公告與通知

Cancer Screening

GASTROClear and LUNGClear in the market, more in the pipeline.

Cancer Treatment Selection

APEX and COMPASS for targeted and comprehensive Next Generation Sequencing (NGS) respectively.

Discovery Genomics

Genomics and bioinformatics services to enhance our partners’ biological system researches.

Cancer Treatment Selection

APEX and COMPASS for targeted and comprehensive Next Generation Sequencing (NGS) respectively.

Discovery Genomics

Genomics and bioinformatics services to enhance our partners’ biological system researches.

Featured

聯繫我們
I Agree